Latest action: Read twice and referred to the Committee on Finance.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill to regulate drug pricing and increase transparency in pharmaceutical costs.
The problem
Americans pay high drug prices compared to other countries. Drug pricing lacks transparency. Healthcare costs burden patients and government programs.
The proposal
Establishes pricing rules for medications. Requires drug makers to report pricing data. May allow government price negotiations for certain drugs.
The impact
Drug companies, patients buying medications, Medicare/Medicaid programs, and taxpayers are affected by pricing changes.
Patients may pay less for medications. Transparency requirements help people understand why drugs cost so much. Government negotiation could reduce prices paid by Medicare.
Medicare and Medicaid could save money through price negotiations. Lower drug costs mean taxpayers spend less on federal health programs.
Requires drug companies to disclose pricing information. Helps patients and doctors make informed choices. Makes the healthcare system more open.
Rules could stop extreme price increases. Protects patients from sudden medication cost spikes.
Lower prices could mean less money for research. Drug companies might develop fewer new medications. Patients could lose access to future treatments.
Pharmaceutical companies may earn less profit. Some companies might reduce research budgets. Could affect jobs in the industry.
Some worry government negotiation is price control. May interfere with free market competition. Could set dangerous precedent for other industries.
Complex rules could be hard to enforce. May require large government bureaucracy. Compliance costs could be passed to consumers.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.